News | October 12, 2021

Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor – Seventh Approval Worldwide for QINLOCK and First European Approval – WALTHAM, Mass.–(BUSINESS WIRE)–Oct. 12, 2021– Deciphera...

News | October 7, 2021

Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – DCC-3116 Shown to Inhibit EGFR and EGFR Family Inhibitor-induced Autophagy in Multiple EGFR-mutant Non-Small Cell...

News | October 7, 2021

Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain PenetrationOctober 7, 2021 at 9:00 AM EDT Currently enrolling APEX, a Phase 2 clinical study of bezuclastinib (CGT9486) for patients with...